The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-05 and is reviewed periodically as new material appears.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
=== Interaction proteomics and protein networks === Interaction proteomics is the analysis of protein interactions from scales of binary interactions to proteome- or network-wide. Most proteins function via protein–protein interactions, and one goal of interaction proteomics is to identify binary protein interactions, protein complexes, and interactomes. Several methods are available to probe protein–protein interactions. While the most traditional method is yeast two-hybrid analysis, a powerful emerging method is affinity purification followed by protein mass spectrometry using tagged protein baits. Other methods include surface plasmon resonance (SPR), protein microarrays, dual polarisation interferometry, microscale thermophoresis, kinetic exclusion assay, and experimental methods such as phage display and in silico computational methods. Knowledge of protein-protein interactions is especially useful in regard to biological networks and systems biology, for example in cell signaling cascades and gene regulatory networks (GRNs, where knowledge of protein-DNA interactions is also informative). Proteome-wide analysis of protein interactions, and integration of these interaction patterns into larger biological networks, is crucial towards understanding systems-level biology.
=== Tolerance dose === In 1931, the U.S. Advisory Committee on X-Ray and Radium Protection (ACXRP, now the National Council on Radiation Protection and Measurements, NCRP), founded in 1929, published the results of a study on the so-called tolerance dose, on which a scientifically based radiation protection guideline was based. Exposure limits were gradually lowered. In 1936 the tolerance dose was 0.1 R/day. The unit "R" (the X-ray) from the CGS unit system has been obsolete since the end of 1985. Since then, the SI unit of ion dose has been "coulomb per kilogram".
The genus Ambrosiella shares at least two nonribosomal peptide synthesis gene clusters with the rest of Ceratocystidaceae encoding intracellular and extracellular siderophores. These products generally help chelate or bind iron for various cellular processes and can be major virulence factors in other fungi; however, seeing as Ambrosiella do not act as serious plant pathogens, the exact role of these peptide products in mediating their relationship with live or decaying tissue has yet to be determined. Unlike serious disease-causing fungi within the Ceratocystidaceae, Ambrosiella possess only half of the full complement of catechol dioxygenases common to this family. These enzymes are generally needed to help fungi metabolize certain plant chemical defenses, and the loss of these genes may reflect this genus's association with individuals that are already weakened or dead and thus less likely to be producing effective antifungal metabolites.
The following mechanism shows a proposed scheme for a metal-dependent "pita-bread" enzyme with residue numbering corresponding to those found in methionine aminopeptidase from E. coli. As shown in Intermediate I of the figure, three potential acidic amino acid residues interact with the N-terminus of the substrate in a fashion that is yet to be determined. The carbonyl and amide groups of the scissile peptide bond interact with the first metal ion, M1, in addition to His178 and His79, respectively. M1 and Glu204 activate a water molecule to prepare it nucleophilic attack at the carbonyl carbon of the scissile peptide bond. Then, the tetrahedral intermediate (Intermediate II) becomes stabilized from interactions with M1 and His178. Lastly, Glu204 donates a proton to the amine of the leaving peptide (P1'). This leads to the breakdown of the intermediate (Intermediate III), which retains its interactions with M1 and His178. The reaction pathway of prolidase is a fairly complicated process with many components involved. After a proton is removed from the bridge between the two Mn2+ ions, the GlyPro substrate causes a conformational change as it binds to the active site. This GlyPro is held in place by hydrogen bonds formed by multiple amino acids in this structure. The Gly-N atom of the GlyPro substrate and the Gly-O atom of the peptide bond each interact with the Mn2+ ions, which are stabilized by additional amino acids, leading to polarization.
== Medical uses == Doxepin is used as a pill to treat major depressive disorder, anxiety disorders, and chronic hives, and for short-term help with trouble remaining asleep after going to bed (a form of insomnia). As a cream it is used for short-term treatment of itchiness caused by atopic dermatitis or lichen simplex chronicus.
Sources: en.wikipedia.org
Despite criticism and international opposition to his controversial anti-narcotics drive, Duterte's domestic approval rating remained relatively high throughout his presidency. Duterte began his presidency with a high trust rating of 79% and 91% (the highest of any Philippine official since 1999), from pollsters Social Weather Stations (SWS) and Pulse Asia, respectively. His net satisfaction rating reached its lowest at 45% in July 2018, attributed to inflation during the period as well as Duterte calling God "stupid" for the concept of original sin in the Bible; eventually, his satisfaction rating rose to 60% by the end of the year. Halfway through his term, Duterte's approval rating reached 79%, the highest among his predecessors at this stage in their presidencies. It rose to 87% by the end of 2019 due to the successful hosting of the 2019 Southeast Asian Games as well as the administration's poverty reduction programs. Amid the COVID-19 pandemic, Pulse Asia reported in September 2020 that 84% of Filipinos approved of the administration's efforts to contain the virus and provide assistance to those who lost their jobs; 92% of the poll respondents also agreed Duterte had "done well" in preventing the contagion in the country. Duterte ended 2021 with an approval rating of 60%, wherein higher net satisfaction was observed among those who have been or are willing to get vaccinated. Duterte maintained his high approval and trust ratings as he approached the end of his term.
While it is constitutionally a multi-party democracy where free elections are regularly held, it functions as a de facto one-party state, with the People's Action Party (PAP) maintaining continuous political dominance since 1959. The PAP's longstanding control has resulted in limited political pluralism and a highly centralised governance structure over national institutions. One of the five founding members of ASEAN, Singapore is also the headquarters of the Asia-Pacific Economic Cooperation Secretariat, the Pacific Economic Cooperation Council Secretariat and is the host city of many international conferences and events. Singapore is also a member of the United Nations, the World Trade Organization, the East Asia Summit, the Non-Aligned Movement and the Commonwealth of Nations.
== Research == The exact mechanism for this protein is currently not known, but efforts continue to isolate activated protein C mutants that lack anticoagulant properties for potential therapeutic use.
Science-Based Medicine emphasized that Ventavia oversaw just three of the 153 clinical sites involved with Pfizer's trial and "a small fraction (~1,000 by the time the whistleblower was fired) of the trial's over ~44,000 subjects." On 10 October 2022, during a session of the European Parliament's Special Committee on the COVID-19 Pandemic, Pfizer executive Janine Small testified that the company had not evaluated the Pfizer–BioNTech COVID-19 vaccine for its ability to reduce transmission of the SARS-CoV-2 virus prior to its release to the general public. Dutch MEP Rob Roos described the admission as "scandalous". CEO Albert Bourla was slated to attend, but withdrew. Roos's statements in turn have been described as "misleading".
Sources: en.wikipedia.org
The basement membrane is visible under light microscopy. Electron microscopy shows that the basement membrane consists of three layers: the lamina lucida (electron-lucent), lamina densa (electron-dense), and lamina fibro-reticularis (electron-lucent). The lamina densa was formerly called the “basal lamina”. The terms “basal lamina” and “basement membrane” were often used interchangeably, until it was realised that all three layers seen with the electron microscope constituted the single layer seen with the light microscope. This has led to considerable terminological confusion; if used, the term “basal lamina” should be confined to its meaning as lamina densa. Some theorize that the lamina lucida is an artifact created when preparing the tissue, and that the lamina lucida is therefore equal to the lamina densa in vivo. The term "basal lamina" is usually used with electron microscopy, while the term "basement membrane" is usually used with light microscopy. Examples of basement membranes include:
=== Other family members === Audrey Conner (Ann Wedgeworth and Debbie Reynolds) – She is the mother of Dan Conner, and the ex-wife of Ed Conner. In Season 2 she is introduced in "We Gather Together" as a friendly, eccentric brunette woman who loves her son and her new boyfriend, as well as her successful career owning a travel agency. It's later revealed that she has a history of mental illness which Dan's father hid from him. She returns in person in season 9, angry at her son for putting her away, seemingly trying to kill him. Her nurse at the mental institution is who Dan had a relationship with while being married to Roseanne. Note, however, that as almost all of season 9 was retconned out of existence, this no longer can be assumed to be 'true' within the show's continuity. (Initially, Dan's affair was revealed to be false, and part of a story Roseanne was writing as a way to deal with Dan's heart-attack death in the previous season. By season 10, even Dan's death was retconned away.) Al Harris (John Randolph) – Al is portrayed as Roseanne and Jackie's henpecked yet humorous father with a knack for telling knock-knock jokes. Al initially appears to have a good relationship with his daughters, especially Jackie, and despite having more in common with her mother, Roseanne finds her father more bearable to be around. Randolph made two appearances as Al Harris during the show's first two seasons. In season four, however, his character changes dramatically. After being unable to secure Randolph for future shows, Al was written out of the series.
== Mission and organisation == The MNHN has as its mission both research (fundamental and applied) and public diffusion of knowledge. It is organised into seven research and three diffusion departments.
The formylglycine tag or aldehyde tag is a convenient 6- or 13-amino acids long tag fused to a protein of interest. The 6-mer tag represents the small core consensus sequence and the 13-mer tag the longer full motif. The experiments on the genetically encoded aldehyde tag by clearly showed the high conversion efficiency with only the core consensus sequence present. Four proteins were produced recombinantly in E.coli with an 86% efficiency of for the full-length motif and >90% efficiency for the 6-mer determined by mass spectrometry. The size of the sequence is analogous to the commonly used 6x His-Tag and has the advantage that it can also be genetically encoded. The sequence is recognized in the ER solely depending on primary sequence and subsequently targeted by FGE. Notably, in the setup of recombinant expression proteins in E. coli a coexpression of exogenous FGE aids full conversion, although E. coli has endogenous FGE-activity. The introduction of an aldehyde tag has a workflow that consists of three segments: A the expression of the fusion protein, that carries the peptide tag derived from the sulfatase motif, B the enzymatic conversion of Cys to f(Gly) and C the bioorthogonal probing with hydrazides or alkoxy amines (Fig. 1).
The protein encoded by this gene is a member of the STAT protein family. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. In response to IFN, this protein forms a complex with STAT1 and IFN regulatory factor family protein p48 (IRF9) and form ISGF-3 (IFN-stimulated gene factor-3), in which this protein acts as a transactivator, but lacks the ability to bind DNA directly. The protein mediates innate antiviral activity. Mutations in this gene result in Immunodeficiency 44. ISGF-3 proceeds the activation of genes via the IFN-stimulated response element (ISRE). ISRE-driven genes include Ly-6C, the double-stranded RNA kinase (PKR), 2´ to 5´ oligoadenylate synthase (OAS), MX and potentially MHC class I. Transcription adaptor P300/CBP (EP300/CREBBP) has been shown to interact specifically with this protein, which is thought to be involved in the process of blocking IFN-alpha response by adenovirus. STAT2 knockout mice are unresponsive to type I IFN and extremely vulnerable to viral infection. They indicate the loss of the type I IFN autocrine loop and several defects in macrophages and T cell responses. Stat2-/- cells show differences in the biological response to IFN-α.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。